OTC · Biotechnology

Clinuvel Pharmaceuticals Limited (CLVLY) Stock

$6.83 -2.57% OTC: CLVLY Healthcare

Clinuvel Pharmaceuticals Limited is a biopharmaceutical firm dedicated to creating and marketing therapies for individuals worldwide grappling with genetic, metabolic, and severe medical conditions, operating across Australia, Europe, the United States, and Switzerland. Their flagship therapeutic, SCENESSE, is a systemic photoprotective medication designed to shield adult patients suffering from erythropoietic protoporphyria (EPP) from light-induced damage.

Valuation

MetricValue
Price$6.83
Market Cap$344.42M
P/E Ratio13.94
P/B Ratio1.82
P/S Ratio4.74
EPS (TTM)$0.49
52-Week High$9.00
52-Week Low$5.98
Dividend Yield0.44%

Financials & Margins

MetricValue
ROE13.29%
ROA12.07%
ROCE15.06%
Gross Margin63.71%
Operating Margin39.39%
Net Margin33.79%
Debt/Equity0.00
Current Ratio14.64

Annual Financials (USD)

Metric20212022202320242025
Revenue$48.0M$66.0M$78.0M$88.0M$95.0M
Operating Profit$27.0M$33.0M$41.0M$48.0M$46.0M
Net Profit$25.0M$21.0M$31.0M$36.0M$36.0M
EPS$0.48$0.40$0.59$0.70$0.72
Op Margin55.6%50.3%52.2%54.4%48.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$109.0M$145.0M$195.0M$231.0M$272.0M
Total Liabilities$10.0M$19.0M$30.0M$28.0M$31.0M
Cash$37.0M$27.0M$24.0M$184.0M$224.0M
Borrowings$1.0M$1.0M$1.0M$1.0M$1.0M

Latest News

NMRK Q2 Deep Dive: Revenue Growth Continues, Margin Pressure and Cautious Outlook Persist StockStory · Aug 4, 2026 Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa PR Newswire · Aug 4, 2026 Investors Are Learning a Hard Lesson About the Dangers of Using Leverage Motley Fool · Aug 4, 2026 eQ unveils a renewed visual identity to support its next phase of growth GlobeNewswire · Aug 4, 2026 Vozinha Arrives in Chile, Escorted by JETOUR Motorcade GlobeNewswire · Aug 4, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$19.0M$40.0M$37.0M$37.0M$41.0M
Investing Cash Flow$-2.0M$-1.0M$-2.0M$-35.0M$-48.0M
Financing Cash Flow$0$0$0$-5.0M$-1.0M
Net Cash Flow$11.0M$-10.0M$-4.0M$3.0M$-7.0M
Free Cash Flow$18.0M$39.0M$36.0M$31.0M$41.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.89
EV / EBITDA10.11
FCF Yield8.78%
Quick Ratio14.17
Interest Coverage11.50
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held0.00%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
Trust For Professional Managers-PMC Diversified Equity Fund4,7822023-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVCTFAvacta Group Plc $0.94 +3.71% -7.36 $440.30M 0.00%
BOVNFBioInvent International AB (publ) $3.29 +0.00% -4.47 $216.40M 0.00%
CMVLFCellectis S.A. $3.47 +12.66% -4.24 $251.93M 0.00%
CYDYCytoDyn Inc. $0.19 +0.00% -5.94 $260.25M 0.00%
FGHQFFrontage Holdings Corporation $0.15 +11.11% 44.83 $304.16M 0.00%

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited is a biopharmaceutical firm dedicated to creating and marketing therapies for individuals worldwide grappling with genetic, metabolic, and severe medical conditions, operating across Australia, Europe, the United States, and Switzerland. Their flagship therapeutic, SCENESSE, is a systemic photoprotective medication designed to shield adult patients suffering from erythropoietic protoporphyria (EPP) from light-induced damage. The company's development portfolio also features CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which stimulates extended cellular activity; and PRÉNUMBRA, an injectable liquid form of afamelanotide. Clinuvel Pharmaceuticals has forged a partnership with HK Winhealth Pharma Group Co. Limited to deliver SCENESSE to EPP patients in the People's Republic of China through a specialized named patient program. Established in 1987, the company maintains its principal office in Melbourne, Australia.

Clinuvel Pharmaceuticals Limited is headquartered in AU.

Clinuvel Pharmaceuticals Limited (CLVLY) stock trades at $6.83 with a market capitalization of $344.42M. The stock is valued at a price-to-earnings (P/E) ratio of 13.94, price-to-book of 1.82, price-to-sales of 4.74. Over the past 52 weeks the stock has ranged between $5.98 and $9.00, and currently trades 24.1% below its 52-week high. It pays a dividend yielding 0.44%.

On profitability, Clinuvel Pharmaceuticals Limited generates a return on equity (ROE) of 13.29%, above the typical market average, return on capital employed of 15.06%, an operating margin of 39.39%, a net profit margin of 33.79%.

Official website: www.clinuvel.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides